论文部分内容阅读
目的观察替吉奥联合多西他赛方案对蒽环类耐药的晚期乳腺癌患者的临床疗效及毒副作用。方法采用替吉奥联合多西他赛方案治疗蒽环类耐药的晚期乳腺癌患者36例。多西他赛75 mg/m2静脉滴注第1天;替吉奥40 mg/m2,2次/d,口服,第1～14 d。每21天重复,至少应用2个周期。结果 36例患者中,完全缓解3例(8.3%)、部分缓解16例(44.4%)、稳定10例(27.8%)、进展7例(19.4%),总有效率52.8%。主要不良反应为骨髓抑制。结论替吉奥联合多西他赛治疗蒽环类耐药的晚期乳腺癌疗效好,不良反应轻,是治疗蒽环类耐药的晚期乳腺癌较好的方案。
Objective To observe the clinical efficacy and toxic side effects of the anti-anthracycline-resistant advanced breast cancer patients treated with the combination of tegaxo and docetaxel. Methods Thirty-six cases of anthracycline-resistant advanced breast cancer patients were treated with the combination of tegafur and docetaxel. Docetaxel 75 mg/m2 intravenously on the first day; Tedio 40 mg/m2, 2 times daily, orally, on the first 14 days. Repeat every 21 days, applying at least 2 cycles. Results Of the 36 patients, 3 (8.3%) were completely relieved, 16 (44.4%) were partially relieved, 10 (27.8%) were stable, and 7 (19.4%) were progressing. The total effective rate was 52.8%. The main adverse reaction was myelosuppression. Conclusions The treatment of anthracycline-resistant advanced breast cancer with the combination of tegafur and docetaxel is effective and has mild adverse reactions. It is a better choice for the treatment of anthracycline-resistant advanced breast cancer.